SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors 24-month HOPE-3 extension data showed slower upper-limb decline among Duchenne patients treated with deramiocel, drawing bullish attention ahead of the FDA decision. Traders view the results as supportive of approval, while others question whether open-label data resolve the FDAs prior statistical concerns; short-squeeze talk is prominent but remains speculative.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure amid concern that its MAX ad platforms growth is nearing a ceiling, competition from Unity could weigh on margins, and securities-fraud lawsuits add uncertainty. Traders are divided: bears see growth risks, while bulls point to e-commerce expansion and AXON install data as signs momentum may be holding up ahead of earnings.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Reports that POET won an ECOC 2026 photonics award have fueled attention and bullish talk around the stocks active trading, with some traders speculating about short covering. Others argue the award matters less than the production, shipment, and customer-order updates they expected, and criticize the companys investor presentation as lacking concrete execution details.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas sharp rerating after positive Phase 3 melanoma-vaccine results and anticipation of fuller INTerpath-001 data at ESMO is meeting resistance from Citis Sell downgrade over valuation concerns. Traders are split between seeing the results as validation of a broader cancer-treatment platform and arguing that expectations have outrun the companys near-term fundamentals, with some also attributing moves to short-covering.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels prostate cancer biomarker findings for CAN-2409, alongside extended Phase 3 data, are driving discussion; bullish traders view the immune-activation evidence as support for the treatments mechanism and BLA case. Others call the findings limited or recycled and remain concerned about the filing timeline and weak share-price action.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is drawing attention for persistent small-cap underperformance as elevated Treasury yields and rate-hike concerns weigh on rate-sensitive, debt-heavy companies. Cooler PCE readings have sparked hopes for lower yields and a rebound, but traders remain divided between a potential bottom and further declines.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

A new change-of-control severance policy has fueled speculation about a potential buyout or strategic investment, though traders note there is no confirmed bidder or deal. Discussion also centers on reported shipment progress for BlueBird 1416, with optimism tempered by calls for firm launch details and frustration over delays.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Staged IPO lockup expirations and reported insider selling are fueling concerns about added share supply and pressure on CBRS, with traders debating whether demand can absorb the shares. Bulls point to Cerebras AI-inference business and customer partnerships, while bears focus on the overhang and sharp stock swings.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Carnivals stronger-than-expected quarterly results and raised guidance have lifted cruise stocks, with traders attributing Norwegians move to a sector-wide sympathy rally. The community sees Norwegian lagging peers and is debating whether heavy short interest could fuel a further bounce, while some remain cautious about the companys performance and management.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is drawing attention amid a sharp long-bond selloff as Treasury yields reach multi-year highs, with traders debating whether inflation and oil risks, expected Fed tightening, and government debt concerns will keep rates elevated. Sentiment is split between calls for further declines and bets that the fund is oversold and could rebound; cooler PCE readings have raised hopes for relief, though some traders question whether the data will sway the bond market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Codexis (CDXS) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Codexis Stock Is Falling After Hours Today

Codexis stock falls after hours after pricing a discounted public offering. Here's why CDXS shares are moving today.read more...

Codexis (CDXS) Q1 2026 Earnings Transcript

Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Fortrea Holdings Inc. (FTRE) Beats Q1 Earnings Estimates

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +426.32% and -0.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Codexis Inc.

Why Did CDXS Stock Jump 7% Today?

Equity

Bearish Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.10	--	--	N/A
Q2 '26	-$0.14	-$0.13	8.24%	BEAT
Q1 '26	-$0.14	-$0.10	26.83%	BEAT
Q4 '25	-$0.03	$0.11	466.67%	BEAT
Q3 '25	-$0.15	-$0.22	-48.08%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CDXS Earnings

Upcoming Earnings: Q3 '26

Historical Earnings